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A combination of olanzapine and samidorphan (OLZ/SAM) received US Food and Drug Administration approval in May 2021 for the
treatment of adults with schizophrenia or bipolar I disorder. OLZ/SAM provides the efﬁcacy of olanzapine, while mitigating
olanzapine-associated weight gain. This exploratory study characterized the metabolic proﬁle of OLZ/SAM in healthy volunteers to
gain mechanistic insights. Volunteers received once-daily oral 10 mg/10 mg OLZ/SAM, 10 mg olanzapine, or placebo for 21 days.
Assessments included insulin sensitivity during an oral glucose tolerance test (OGTT), hyperinsulinemic-euglycemic clamp, other
measures of glucose/lipid metabolism, and adverse event (AE) monitoring. Treatment effects were estimated with analysis of
covariance. In total, 60 subjects were randomized (double-blind; placebo, n = 12; olanzapine, n = 24; OLZ/SAM, n = 24). Olanzapine
resulted in hyperinsulinemia and reduced insulin sensitivity during an OGTT at day 19, changes not observed with OLZ/SAM or
placebo. Insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp, was decreased in all treatment groups relative to
baseline, but this effect was greatest with olanzapine and OLZ/SAM. Although postprandial (OGTT) glucose and fasting cholesterol
concentrations were similarly increased with olanzapine or OLZ/SAM, other early metabolic effects were distinct, including postOGTT C-peptide concentrations and aspects of energy metabolism. Forty-nine subjects (81.7%) experienced at least 1 AE, most mild
or moderate in severity. OLZ/SAM appeared to mitigate some of olanzapine’s unfavorable postprandial metabolic effects (e.g.,
hyperinsulinemia, elevated C-peptide) in this exploratory study. These ﬁndings supplement the body of evidence from completed
or ongoing OLZ/SAM clinical trials supporting its role in the treatment of schizophrenia and bipolar I disorder.
Neuropsychopharmacology (2022) 47:696–703; https://doi.org/10.1038/s41386-021-01244-7

INTRODUCTION
Antipsychotic pharmacotherapy is the cornerstone of treatment
for schizophrenia, but this class of medications has been
associated with the development of metabolic sequelae, including
increased risk of type 2 diabetes [1, 2]. A large population cohort
study from Denmark found that the risk of developing diabetes
was more than threefold higher in individuals with schizophrenia
compared with those without schizophrenia. In addition, incident
diabetes risk was increased more than threefold with antipsychotic treatment vs. no treatment, and the risk of diabetes
development was similar between ﬁrst-generation antipsychotics
(adjusted hazard ratio, 3.06; 95% conﬁdence interval [CI],
1.32–7.05) and second-generation antipsychotics (adjusted hazard
ratio, 3.44; 95% CI, 1.73–6.83) when compared among patients
who were antipsychotic naive, and after adjustment for potential
confounders, including a family history of diabetes [3].
Of the available antipsychotic treatments used for schizophrenia, the risk of incident diabetes and dyslipidemia is higher with
olanzapine than with other agents [4–6]. This, along with the risk

of substantial weight gain [1, 7, 8], has limited olanzapine’s overall
clinical utility [9, 10]. Although the signiﬁcant weight gain
associated with olanzapine is likely to impose metabolic
perturbations over the long term, studies in healthy volunteers
and patients with schizophrenia have revealed that changes in
glucose and lipid metabolism can occur quickly, as early as 3 days
after starting olanzapine treatment [11–14]. Therefore, apart from
the long-term metabolic impact of weight gain, the initial
metabolic changes associated with olanzapine likely reﬂect
weight-independent pharmacodynamic effects of the drug.
A combination of olanzapine and samidorphan (OLZ/SAM) has
been approved by the US Food and Drug Administration for the
treatment of adults with schizophrenia or bipolar I disorder [15].
Olanzapine is among the most effective antipsychotic agents
available [1, 8]. Samidorphan, a new molecular entity, binds
in vitro with high afﬁnity to human µ-, κ-, and δ-opioid receptors,
and acts as an antagonist at μ-opioid receptors and as a partial
agonist at κ- and δ-opioid receptors [16, 17]. In vivo, samidorphan
functions as an opioid receptor antagonist [18]. The addition of
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Fig. 1 Study design schematic. After screening and a run-in period, subjects were admitted to the clinic on day −5 and were subsequently
randomized on day 1 to placebo, olanzapine, or OLZ/SAM for 21 days. The study assessed a variety of prespeciﬁed endpoints related to
glucose, lipid, and energy metabolism. Assessments taken during the inpatient period are depicted in the table. Prior to days when metabolic
tests (i.e., OGTT, MMTT, clamp, or indirect calorimetry procedures) were scheduled, subjects received a standardized dinner and were required
to fast for 10 h prior to the procedure. DEXA, dual energy x-ray absorption; EGP, endogenous glucose production; MMTT, mixed-meal
tolerance test; OGTT, oral glucose tolerance test; OLZ/SAM, combination of olanzapine and samidorphan. aSubjects could choose meals (30%
to 45% fat content) or other snacks. bTwo-step hyperinsulinemic-euglycemic clamp assessed by infusion of stable isotope-labeled glucose.
Labeled glucose was also administered prior to the clamp procedure to determine fasting endogenous glucose production. cAssessments of
energy metabolism included resting metabolic rate, respiratory quotient, and substrate oxidation.

samidorphan mitigates olanzapine-associated weight gain without compromising the established antipsychotic efﬁcacy of
olanzapine [19–21].
Preclinically, samidorphan reduced the rate of weight gain and
mitigated some metabolic abnormalities when co-administered
with olanzapine [22]. In clinical studies, the weight-mitigating
effects of samidorphan are observed as early as 4–6 weeks after
initiating treatment [19, 23]. However, whether the two treatments
differentiate on early metabolic effects is unknown. This 3-week,
exploratory, mechanistic study sought to characterize short-term
effects of OLZ/SAM relative to olanzapine on insulin sensitivity and
additional metabolic parameters, including endogenous glucose
production, lipid metabolism, energy intake, and energy expenditure, among others. Healthy volunteers were enrolled to avoid
metabolic confounders, such as weight, metabolic irregularities,
smoking, and/or prior exposure to antipsychotics or mood
stabilizers, which may be present in patients with schizophrenia
[2, 24, 25]. The use of healthy volunteers negated the predisposition to metabolic derangements associated with severe mental
illness and precluded the need to monitor schizophrenia symptom
status during the study. Furthermore, concern that the multiple,
intensive study procedures may have been perceived as too
intrusive for patients with schizophrenia provided further support
for conducting the study in healthy volunteers. Finally, healthy
volunteers were enrolled owing to the exploratory and
hypothesis-generating nature of the study, with the intention of
providing a guide for future studies in patients with schizophrenia.
METHODS
This phase 1, randomized, double-blind, parallel-group, single-center study
in healthy volunteers (NCT02922426) was conducted from September
2016 to July 2017 in accordance with the ethical principles of the
Declaration of Helsinki and with the International Council for Harmonisation Good Clinical Practice guidelines. Study materials and the protocol
were reviewed and approved by an institutional review board/independent ethics committee. All participants provided written, informed consent
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before initiation of any study-speciﬁc procedures. The samidorphan dose
used in this study (10 mg in OLZ/SAM) was previously identiﬁed as the
optimal dose for efﬁcacy, tolerability, and weight gain mitigation in
patients with schizophrenia receiving OLZ/SAM [19]. A 10 mg dose of
olanzapine was utilized in OLZ/SAM and as monotherapy, because it is the
maximum tolerated dose for repeat administrations in healthy subjects.

Study design
This 3-week study included a screening visit, 3-day run-in period, inpatient
period, and follow-up visit (Fig. 1). During the in-house run-in period, no
active treatments were given, but subjects wore an activity monitor and
recorded their food consumption in a diary. Subjects remained at the study
site for ~29 days, starting on day −5. On day 1, subjects were randomized
2 : 2 : 1 in a double-blind manner using a single master randomization
schedule generated by an independent vendor (ProSciento, Inc., Chula Vista,
CA) to once-daily, oral OLZ/SAM, olanzapine, or placebo for 21 days, during
which time study investigators and subjects were blinded to treatment. A
follow-up safety assessment occurred ~2 weeks after subjects left the study
site. Metabolic and body composition assessments were conducted before,
during, and at the end of the treatment period (Fig. 1). There was no formal
sample size calculation, as the study was exploratory in nature.

Study population
Eligible subjects were adults 18–40 years of age, with a body mass index of
18 to <25 kg/m2 at screening and randomization. Subjects had stable body
weight that had not changed more than 4% in the preceding 2 months.
Subjects were excluded for the presence of a clinically signiﬁcant medical
or psychiatric condition, laboratory abnormality, or history of suicidal
ideation or behavior (as assessed by the Columbia-Suicide Severity Rating
Scale [C-SSRS] [26] at screening and clinic admission). In addition, a history
of diabetes, hemoglobin A1c (HbA1c) levels >5.7% or low neutrophil count
(≤1.5 × 103/μL) at screening, engagement in regular structured exercise
(>30 min daily on ≥3 days/week), dependence on any substance other
than caffeine [27], or history of regular smoking or nicotine use were
exclusionary. Subjects were also excluded based on known or suspected
intolerance, allergy, or hypersensitivity to olanzapine or opioid antagonists,
current or anticipated use of prescribed opioids (e.g., for a planned
surgery), or positive urine screen for amphetamines, barbiturates,
cannabinoids, or cocaine.
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Table 1.

Demographics and subject characteristics at screening: pharmacodynamics population.

Parameter

Placebo (n = 12)

Olanzapine (n = 24)

OLZ/SAM (n = 24)

Male, n (%)

10 (83.3)

20 (83.3)

19 (79.2)

Age, mean (SD), years

30.0 (7.2)

28.0 (4.7)

28.0 (5.0)

7 (58.3)

20 (83.3)

10 (41.7)

Race, n (%)
White
Black or African American

5 (41.7)

2 (8.3)

13 (54.2)

American Indian/Alaska native

0

0

1 (4.2)

Asian

0

1 (4.2)

0

Multiple races

0

1 (4.2)

0

Weight, mean (SD), kg

69.6 (7.0)

70.7 (7.5)

71.4 (7.7)

Body mass index, mean (SD), kg/m2

23.0 (1.9)

23.2 (1.3)

23.5 (1.2)

Percentage body fat, mean (SD)

23.5 (10.8)

24.7 (8.6)

22.6 (10.8)

Fat-free mass,a mean (SD), kg

53.5 (9.0)

53.4 (8.8)

55.3 (9.7)

HbA1c, mean (SD), %

5.2 (0.3)

5.4 (0.2)

5.3 (0.2)

HbA1c hemoglobin A1c, OLZ/SAM combination of olanzapine and samidorphan.
a
Fat-free mass was measured at the baseline visit.

Assessments
Although the study was exploratory in nature, a variety of pharmacodynamic assessments were prespeciﬁed for the purpose of measuring effects
on carbohydrate and lipid metabolism, energy expenditure, and food
intake (see details in Supplementary Materials). A schematic of the clamp
procedure is provided in Supplementary Fig. S1.

Statistical analysis
The primary objective of this study was to characterize insulin sensitivity, as
well as changes in carbohydrate and lipid metabolism, following treatment
with OLZ/SAM and olanzapine. Because of the exploratory nature of the
study, there were no prespeciﬁed primary or key secondary outcomes and
no control for multiplicity. Safety was assessed from all randomized
subjects who received at least 1 dose of study drug; pharmacodynamic
assessments were conducted in subjects who received at least 1 dose of
study drug and who adequately complied with the protocol (no deviations
related to investigational product intake) as determined by the sponsor
and had sufﬁcient data for at least 1 pharmacodynamic or body
composition endpoint. Analysis of covariance (ANCOVA) was used to
assess treatment effects on metabolic endpoints. There was a higher
proportion of black or African American subjects in the OLZ/SAM and
placebo groups vs. the olanzapine group after randomization. Consequently, adjustments were made to the regression model to correct for the
race imbalance. Speciﬁcally, the ANCOVA model included treatment as a
factor and the baseline of the dependent variable and race (black/African
American or not) as covariates. Results are presented as least square (LS)
means or geometric LS mean (GLSM) ratios with 90% CIs. The analysis of
pharmacodynamic endpoints was based on observed results, without
imputation for missing data. Safety variables, including weight, were
summarized using descriptive statistics. Reported adverse events (AEs)
were coded using the Medical Dictionary for Regulatory Activities v19.1
based on preferred terms and system organ class categories.

RESULTS
Subject disposition
Of 130 subjects screened, 60 met eligibility criteria and were
randomized, 12 to the placebo group, and 24 each to the
olanzapine and OLZ/SAM groups (Supplementary Fig. S2). All
60 subjects were included in assessments of pharmacodynamics
and safety. In total, 52 (86.7%) subjects completed the study: 11
(91.7%) in the placebo group, 22 (91.7%) in the olanzapine group,
and 19 (79.2%) in the OLZ/SAM group. Reasons for early
discontinuation were AEs (n = 6 overall [10.0%]; 2 from the
olanzapine group and 4 from the OLZ/SAM group) or withdrawal
by the subject (n = 2 overall [3.3%]; 1 each from the placebo and
OLZ/SAM groups).

Baseline characteristics
Most subjects were male (81.7%) and the overall mean (SD) age
was 28.4 (5.4) years. The three treatment groups were balanced at
baseline for sex, age, weight, body mass index, percentage body
fat, and HbA1c levels (Table 1). Despite randomization, more
White subjects were included in the olanzapine group.
Pharmacodynamic parameters
Fasting glucose, insulin, and homeostatic model of insulin resistance.
Fasting glucose concentrations were similar at baseline across the
three treatment groups, with similar decreases across all groups
from baseline to day 22. For fasting insulin, a small decrease was
observed for placebo compared with small similar increases
observed with both olanzapine and OLZ/SAM (Supplementary
Table S1).
Small changes in the homeostatic model of insulin resistance
were observed in all treatment groups from baseline to day 22,
with olanzapine and OLZ/SAM both resulting in small numeric
increases compared with a decrease observed with placebo
(Supplementary Table S1).
Fasting lipids and adipokines. Fasting total cholesterol and lowdensity lipoprotein cholesterol increased similarly with olanzapine
and OLZ/SAM from baseline to day 22; the increases were larger
than the changes observed with placebo. Triglycerides also
increased for olanzapine, but increases were minimal and similar
for OLZ/SAM and placebo treatment. high-density lipoprotein
cholesterol decreased comparably across all treatment groups
from baseline to day 22 (Supplementary Table S1). Leptin
increased similarly for both olanzapine and OLZ/SAM (LS mean
change [90% CI]: 2.09 [0.52, 3.67] and 2.31 [0.93, 3.69],
respectively) and the increases were larger than that observed
for placebo (0.33 [−1.73, 2.38]).
Plasma concentrations of glucose, insulin, and C-peptide during
tolerance tests. Glucose, insulin, and C-peptide concentrations
were measured before and at intervals following an oral glucose
tolerance test (OGTT) (Supplementary Fig. S3A). At baseline, the
area under the concentration vs. time curve for glucose (AUCGlu)
was similar across all treatment groups (mean [SD] values of
442.07 [75.01], 425.21 [70.98], and 396.47 [48.14] h*mg/dL,
respectively, for placebo, olanzapine, and OLZ/SAM). When the
OGTT was repeated at day 19, there were small changes in all
groups from baseline in AUCGlu (mean change [SD] of −6.29
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Fig. 2 Ratios of glucose, insulin, and C-peptide concentrations
and changes in the Matsuda Index. The effects of olanzapine and
OLZ/SAM on postprandial glucose-related parameters were
assessed after oral administration of 75 g of glucose for 180 min
(OGTT) or (2) 8-ounce bottles of Ensure Plus for 360 min (MMTT).
The ratio of change in glucose, insulin, and C-peptide values at day
19 relative to baseline for the OGTT (Fig. 2A) and at day 18 relative to
baseline for the MMTT (Fig. 2C) were determined using ANCOVA
models, with treatment as a factor and baseline of the dependent
variable and race (black/African American or not) as covariates.
Changes in insulin sensitivity at day 19, calculated as the Matsuda
index from OGTT results, are shown by treatment group (Fig. 2B).
Decreases in the Matsuda index indicate a decline in insulin
sensitivity. ANCOVA, analysis of covariance; AUC0-180, area under the
plasma concentration-time curve from time 0 to 180 min; AUC0-360,
area under the plasma concentration-time curve from time 0 to 360
min; CI, conﬁdence interval; LS, least squares; MMTT, mixed-meal
tolerance test; OGTT, oral glucose tolerance test; OLZ/SAM,
combination of olanzapine and samidorphan.
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h*µU/mL, respectively; Supplementary Fig. S3A). Relative changes
in AUCinsulin for day 19 compared with baseline are shown in
Fig. 2A. Consistent with the increases in insulin observed with
olanzapine treatment, greater increases were noted in C-peptide
from baseline to day 19 for olanzapine.
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1.367
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[61.07], 15.92 [39.09], and 22.57 [50.30] h*mg/dL, respectively, for
placebo, olanzapine, and OLZ/SAM). Figure 2A depicts relative
changes in AUC for glucose, insulin, and C-peptide at day 19 vs.
baseline.
Larger group differences were observed for changes in
AUCinsulin from baseline to day 19 (Fig. 2A). At baseline, AUCinsulin
was generally similar across the three treatment groups (mean
[SD] values of 282.73 [204.47], 223.71 [130.88], and 208.13 [163.36]
h*µU/mL, respectively, for placebo, olanzapine, and OLZ/SAM).
When the OGTT was repeated on day 19, there was an increase
from baseline in AUCinsulin for olanzapine (mean [SD] change of
91.64 [94.35] h*µU/mL) that was not observed with OLZ/SAM or
placebo (mean [SD] changes of −17.46 [100.73] and −2.96 [80.60]
Neuropsychopharmacology (2022) 47:696 – 703

Insulin secretion and insulin sensitivity during the OGTT. Glucose
and insulin concentrations during the OGTT were used to estimate
insulin sensitivity by the Matsuda index. At baseline, the Matsuda
index was similar across the three treatment groups (mean [SD] of
3.71 [1.61], 3.91 [2.09], and 4.63 [1.95] for placebo, olanzapine, and
OLZ/SAM groups, respectively). Based on the Matsuda index, there
was a numeric increase from baseline at day 19 for placebo (mean
change [SD] of 0.46 [1.06]) compared with a decrease observed
with olanzapine (mean [SD] of −0.59 [1.44]). A smaller decrease
was observed with OLZ/SAM (−0.13 [2.40]). The GLSM ratio [90%
CI] of the Matsuda index at day 19 compared with baseline for all
treatment groups is shown in Fig. 2B.
Olanzapine treatment resulted in an increase in the insulinogenic index (Δ0–30 min insulin/Δ0–30 min glucose) at day 19
compared with baseline (GLSM ratio [90% CI] of 1.46 [1.20, 1.77]).
No signiﬁcant increases were observed for placebo or OLZ/SAM
between baseline and day 19 (GLSM ratios of 1.12 [0.94, 1.32] and
1.14 [0.90, 1.44], respectively).
Mixed-meal tolerance test. AUC proﬁles during the mixed-meal
tolerance test (MMTT) are depicted in Supplementary Fig. S3B; the
ratio of glucose, insulin, and C-peptide concentrations at day 18
relative to baseline are presented in Fig. 2C. Overall, small, similar
increases in post-challenge AUCglu were observed for all treatment
groups at day 18 relative to baseline. Increases in post-challenge
insulin and C-peptide (AUC0–300) were also observed in all groups
from baseline to day 18. However, in line with ﬁndings from the
OGTT, increases for olanzapine were numerically greater than
those observed with OLZ/SAM and placebo.
Hepatic insulin resistance index. In an additional analysis, hepatic
insulin sensitivity in the fasting state (also referred to as the
hepatic insulin resistance [HIR] index) was assessed at baseline,
day 10, and day 21. At baseline, values for HIR [28] corrected for
fat-free mass were generally similar across treatment groups
(mean [SD] of 12.93 [6.17], 16.20 [8.33], and 13.87 [6.99] nIU/L/min,
respectively, for placebo, olanzapine, and OLZ/SAM). At day 10,
compared with baseline, there was a small, nonsigniﬁcant increase
in the HIR index in the placebo group (LS mean [90% CI] change of
1.47 [−1.93, 4.87] nIU/L/min), with larger, signiﬁcant increases
from baseline observed with olanzapine and OLZ/SAM (4.38 [1.55,
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7.22] and 3.14 [0.64, 5.64] nIU/L/min, respectively). At day 21, the
HIR index remained elevated for olanzapine (LS mean change
[90% CI] of 4.89 [2.30, 7.47] nIU/L/min) but had returned to
baseline for OLZ/SAM and placebo (LS mean changes of −0.52
[−2.79, 1.75] and −0.83 [−3.83, 2.17] nIU/L/min, respectively;
Supplementary Fig. S4).
Hyperinsulinemic-euglycemic clamp. To assess insulin sensitivity
during the clamp procedure, a composite insulin sensitivity index
(Si) was derived based on glucose infusion rates during both
clamp steps (i.e., Step 1 and Step 2; Fig. 3 and Supplementary
Table S2). At baseline, Si (corrected for fat-free mass) was similar
across all treatment groups. At day 10, Si decreased, indicating a
worsening peripheral insulin sensitivity, for all treatment groups.
Decreases in Si were similar for olanzapine and OLZ/SAM, and
were larger than those observed with placebo. At day 21, Si
continued to be decreased from baseline in all treatment groups
but to a lesser extent than at day 10. Decreases in Si at day 21
continued to be similar for olanzapine and OLZ/SAM, and larger
than that observed with placebo.
Body weight and composition. Similar increases in body weight
from baseline to day 22 were observed for olanzapine and OLZ/
SAM (LS mean change [90% CI] of 2.87 [2.09, 3.65] kg and 3.16
[2.47, 3.84] kg, respectively); these increases were larger than that
found with placebo (LS mean change [90% CI] of 0.57 [−0.44,
1.58] kg). Increases in fat mass were observed in all groups, with
the largest increases occurring in subjects treated with olanzapine
or OLZ/SAM (LS mean change [90% CI] of 1.79 [1.36, 2.23] kg and
1.97 [1.57, 2.37] kg, respectively, vs. 0.64 [0.10, 1.18] kg for
placebo). Accordingly, there were increases in percent body fat
from baseline to day 22 in all treatment groups, with larger
increases for olanzapine (1.68% [1.17, 2.20]) and OLZ/SAM (1.89%
[1.42, 2.36]) compared with placebo (0.82% [0.18, 1.46]). Fat-free
mass increased during treatment with olanzapine (1.13 [0.52,
1.74] kg) and OLZ/SAM (0.87 [0.31, 1.43] kg), but mean changes in
fat-free mass with placebo were minimal (−0.06 [−0.81, 0.70] kg).
Caloric intake and energy expenditure. Caloric intake was
measured at two single buffet-style meals: one at baseline and
one at the end of the 3-week treatment period. At baseline, the
mean (SD) total caloric intake was 1894.6 (488.2) kcal for placebo,
2198.3 (605.3) kcal for olanzapine, and 2374.0 (804.0) kcal for OLZ/
SAM. Caloric intake increased in the placebo and olanzapine
LS Mean (90% CI) Change From Baseline
(mL mL/min/PIU/kg)
Insulin Sensitivity Index
Day 10
Placebo (n=12)
Olanzapine (n=24)
OLZ/SAM (n=22)
Day 21
Placebo (n=11)
Olanzapine (n=23)
OLZ/SAM (n=19)

groups at day 22 (LS mean change [90% CI] of 92.6 [−188.98,
374.22] kcal and 201.6 [−10.90, 414.15] kcal, respectively), with the
increase being more pronounced for olanzapine; Supplementary
Fig. S5). In contrast, subjects in the OLZ/SAM treatment group
consumed fewer calories at day 22 (LS mean change [90% CI] of
−297.6 [−495.64, −99.55] kcal).
There were small mean increases in resting energy expenditure
in all treatment groups. The greatest increase was observed for
olanzapine (LS mean change [90% CI] of 67.9 [−13.64, 149.38]
kcal/day), whereas changes for OLZ/SAM and placebo were similar
(19.4 [−57.51, 96.38] kcal/day and 20.0 [−81.14, 121.24 kcal/day],
respectively). Patients treated with olanzapine had an increased
respiratory quotient over the 3-week treatment period (LS mean
change from baseline to day 22 in ratio of CO2 eliminated/O2
consumed [90% CI]: 0.025 [0.01, 0.04]), which was larger than the
changes from baseline with placebo (−0.002 [−0.03, 0.02]) or OLZ/
SAM (0.003 [−0.02, 0.02]).
Carbohydrate oxidation increased from baseline to day 22 with
olanzapine (LS mean change [90% CI]: 30.1 [4.97, 55.24] g/day),
whereas placebo and OLZ/SAM were associated with smaller
changes (−3.1 [−34.27, 28.02] g/day and 2.0 [−22.06, 26.11] g/day,
respectively). Treatment with olanzapine resulted in decreased fat
oxidation (LS mean change [90% CI]: −11.3 [−21.89, −0.79] g/
day), whereas treatment with placebo or OLZ/SAM resulted in
numeric increases (6.0 [−6.87, 18.96] g/day and 1.2 [−8.95, 11.27]
g/day, respectively). Changes in protein oxidation were observed
in all groups; however, there was a numeric decrease for placebo
(LS mean change, −9.6 [−22.12, 3.01] g/day), whereas there were
increases for olanzapine and OLZ/SAM (5.9 [−4.36, 6.18] g/day and
2.8 [−7.00, 12.63] g/day, respectively).
Safety
In total, 49 of 60 subjects (81.7%) experienced at least 1 AE, with 9
(75.0%), 19 (79.2%), and 21 (87.5%) subjects reporting at least 1 AE
during treatment with placebo, olanzapine, and OLZ/SAM,
respectively (Table 2). Most AEs were mild (45 subjects; 75.0%)
or moderate (3 subjects; 5.0%); only 1 (1.7%) subject experienced
an AE of severe intensity (muscle spasm with olanzapine). In the
six subjects who discontinued because of an AE, all AEs were mild
or moderate in severity. AEs led to study discontinuation in two
subjects on olanzapine (increased alanine aminotransferase in
both) and in four subjects (six events) treated with OLZ/SAM
(increased alanine aminotransferase [two subjects], increased
aspartate aminotransferase [two subjects], dizziness [one subject],
Table 2.

-0.041

Summary of adverse events.

Parameter

Placebo
(n = 12)

Olanzapine
(n = 24)

OLZ/SAM
(n = 24)

Subjects with any AE,
n (%)

9 (75.0)

19 (79.2)

21 (87.5)

0

11 (45.8)

6 (25.0)

-0.103
-0.086

AEs occurring in ≥10%
of subjects,a n (%)

-0.036
-0.064
-0.064

-0.15

-0.10

-0.05
Decrease From
Baseline

0.00

0.05
Increase From
Baseline →

→

Fig.
3 Insulin
Sensitivity
Index
(Si)
derived
from
hyperinsulinemic-euglycemic clamp measurements at day 10
and day 21 of treatment. Insulin sensitivity decreased with
olanzapine, especially at day 10 but also at day 21. OLZ/SAM
treatment produced similar changes. LS means were generated
using ANCOVA, with treatment as a factor and baseline for the
dependent variable and race (black/African American or not) as
covariates. ANCOVA, analysis of covariance; CI, conﬁdence interval;
LS, least squares; M, glucose disposal rate based on the glucose
infused per minute, corrected for fat-free mass; OLZ/SAM, combination of olanzapine and samidorphan.

Increased alanine
aminotransferase
Fatigue

1 (8.3)

7 (29.2)

7 (29.2)

Somnolence

0

2 (8.3)

7 (29.2)

Constipation

1 (8.3)

0

7 (29.2)

Dry mouth

0

0

8 (33.3)

Headache

2 (16.7)

1 (4.2)

5 (20.8)

Dizziness

2 (16.7)

0

5 (20.8)

0

2 (8.3)

5 (20.8)

Increased aspartate
aminotransferase

AE adverse event, OLZ/SAM combination of olanzapine and samidorphan.
a
In the overall safety population.
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and fatigue [one subject]). No deaths or serious AEs were reported.
AEs reported in at least ﬁve subjects in any treatment group were
increased alanine aminotransferase, fatigue, somnolence, dry
mouth, constipation, headache, increased aspartate aminotransferase, and dizziness (Table 2).
Clinically meaningful changes in weight (≥7% increase from
baseline) occurred in 2 (16.7%), 9 (37.5%), and 6 (27.3%) subjects
treated with placebo, olanzapine, and OLZ/SAM, respectively.
Mean changes in blood pressure, heart rate, respiratory rate, and
temperature were not considered clinically meaningful; in
addition, no clinically meaningful changes occurred in hematology or ECG results. No subjects reported suicidal ideation or
behavior, as assessed by changes in C-SSRS scores.
DISCUSSION
This short-term exploratory study replicated ﬁndings from
previous studies in healthy volunteers in which olanzapine
treatment induced early impairments in insulin sensitivity and
lipid parameters that preceded weight gain [29–31]. The present
study also identiﬁed early differences in the metabolic effects of
olanzapine and OLZ/SAM that preceded the timing of divergences
in weight trajectories that were previously reported [19, 23]. The
insulin and C-peptide responses during an OGTT and changes in
the insulinogenic index suggest a heightened insulin secretory
response with olanzapine treatment but not with OLZ/SAM. As the
AUCGlu was similar between groups at baseline and there were
similar small changes in both groups at day 19, this ﬁnding
suggests a loss of insulin sensitivity associated with olanzapine
treatment that did not occur to the same extent with OLZ/SAM.
This ﬁnding is more clearly appreciated with the Matsuda index, a
surrogate marker of insulin sensitivity that is calculated from
glucose and insulin responses. Compared with placebo, olanzapine was associated with a marked reduction in the Matsuda
index at day 19, whereas decreases were attenuated with OLZ/
SAM.
Although no signiﬁcant differences were observed between
groups, the results of the MMTT were consistent with those of the
OGTT. Similar changes in post-challenge glucose levels were
observed in all treatment groups, but marked post-challenge
hyperinsulinemia was observed with olanzapine, which superseded that observed with OLZ/SAM or placebo.
Olanzapine-induced hyperinsulinemia has been observed previously in studies of patients with schizophrenia [32, 33] and
healthy volunteers [30, 34]. The ﬁndings of this study are
consistent with reports that hyperinsulinemia results from
increases in insulin secretion from the pancreas. Multiple
mechanisms may account for olanzapine-mediated increases in
insulin secretion, including alterations in neuronal modulation of
the pancreas and even direct effects of dopamine receptor
antagonism on pancreatic β-cells [35–37]. One study of intravenous glucose tolerance tests in healthy volunteers treated with
olanzapine demonstrated an essential role of sympathetic input
via muscarinic receptors in mediating the olanzapine-induced
hyperinsulinemic response to glucose challenge [34]. More
recently, it has been reported that pancreatic α- and β-cells not
only express D2-like dopamine receptors but also are capable of
local catecholamine synthesis [36]. The evidence suggests that
antipsychotic-induced blockade of dopamine receptors may
release dopamine-mediated inhibition of insulin secretion, leading
to an increase in glucose-stimulated insulin secretion [35, 36].
The mechanisms through which samidorphan may attenuate
this glucose-stimulated hyperinsulinemia are not clear. Although
olanzapine and samidorphan target different receptors and likely
act through distinct signaling pathways, it is possible that both
pathways could converge on the same physiologic processes (i.e.,
insulin secretion). A role for the opioid system in regulating
glucose homeostasis and the insulin secretory response has been
Neuropsychopharmacology (2022) 47:696 – 703

established for decades [38–41]. Based on early studies, morphineand β-endorphin-induced hyperglycemia result from both central
and peripheral effects on the pancreas-adrenal axis and the
pancreas [42, 43]. The opioid antagonist naltrexone has been
reported to prevent the glucose-stimulated hyperinsulinemia
associated with polycystic ovary syndrome [44]. Endogenous
opioid peptides and μ- and δ-opioid receptors have been
identiﬁed in pancreatic islets of various species, and opioids
appear to exert both stimulatory and inhibitory effects on insulin
secretion, depending on the concentration [38, 39, 45, 46]. These
effects may be mediated by direct signaling on the β-cell and by
potentiation of somatostatin signaling within the pancreas that
inhibits insulin secretion [38, 39, 45, 46]. Taken together, there is
an established role for opioidergic regulation of glycemic
response at multiple levels (central and peripheral); therefore, it
is feasible that samidorphan works independently, through
opioid-related mechanisms, to oppose olanzapine’s hyperinsulinemic effects.
The higher the rates of endogenous glucose production and the
higher the levels of fasting plasma insulin concentrations, the
greater the HIR (and, typically, the more impaired is the hepatic
insulin sensitivity) [47, 48]. Similar to the decreased insulin
sensitivity detected with the Matsuda index over 3 weeks,
olanzapine treatment also decreased hepatic insulin sensitivity,
as assessed by the HIR index, whereas OLZ/SAM did not to the
same degree. These ﬁndings suggest that the addition of
samidorphan to olanzapine as OLZ/SAM may attenuate the
negative effects of olanzapine on hepatic insulin sensitivity.
The ﬁndings on the Matsuda index and HIR index that
samidorphan attenuated the effects of olanzapine on insulin
sensitivity at day 21 are in contrast with data from the
hyperinsulinemic-euglycemic clamp. For example, by clamp, both
olanzapine and OLZ/SAM decreased insulin sensitivity with 10 days
of treatment. However, by day 21, the changes in insulin sensitivity
in both the olanzapine and OLZ/SAM groups were attenuated, with
90% CIs for the mean percent change from baseline in either active
treatment group overlapping with those in the placebo group. The
reason for this incongruence is unknown, but it is worth noting
that the methodologies employed in this study assess glucose
metabolism under different conditions.
As suggested by its name, the hyperinsulinemic-euglycemic
clamp artiﬁcially establishes a state of constant hyperinsulinemia
and euglycemia to measure how effectively insulin affects glucose
uptake from blood. This experimental paradigm does not take into
account other endogenous mechanisms that regulate glucose
homeostasis under physiologic conditions, including changes in
counter-regulatory hormones and neural endocrine responses to a
meal. In contrast, the experimental conditions of the OGTT and
MMTT reﬂect the body’s integrated response to a glucose
challenge originating from the gastrointestinal tract, which
involves more complex glucoregulatory changes, including gut
hormone secretion, changes in glucagon secretion, and even
glucose effectiveness [49] (i.e., the ability of glucose itself to
suppress hepatic glucose production). The incongruence in results
from the OGTT and clamp, therefore, suggests the possibility that
OLZ/SAM and olanzapine differ primarily in how they affect those
other endogenous mechanisms regulating glucose homeostasis,
rather than in how they affect insulin signaling itself. A limitation
of the current study is that aspects of glucose regulation, such as
glucagon secretion and glucose effectiveness [49], were not
measured.
This possibility is further supported by the similarity of results
between the OGTT and MMTT. Although no statistical separation
was observed, in both tests the elevated insulinogenic response
with olanzapine was blunted with OLZ/SAM. Further research is
needed to understand the precise mechanisms through which
OLZ/SAM and olanzapine differentially regulate glucose homeostasis under physiologic conditions.
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Although not the main focus of this study, caloric intake
increased with olanzapine but decreased with OLZ/SAM. Both
groups gained similar amounts of weight, but the opposing
changes in caloric intake at endpoint may underlie the differential
weight gain observed in longer studies, in which weight gain is
similar for the ﬁrst 4 to 6 weeks and then diverges [19, 21].
Olanzapine was also associated with an increased respiratory
quotient and numerically greater resting energy expenditure not
observed with OLZ/SAM or placebo, consistent with a previous
study in healthy volunteers [50].
The ﬁndings from this study should be interpreted considering
the following limitations. First, this study was exploratory in
nature, with no predeﬁned hypotheses and no correction for the
multiple comparisons made. Second, this study was conducted in
a relatively small number of healthy subjects who may have
different tolerability to antipsychotic drugs than other patient
populations [51]. As the study enrolled healthy volunteers, the
dose of olanzapine could not exceed 10 mg, which is likely lower
than doses administered to patients [52] (e.g., large population
studies reported a median dose of 11.7 mg in outpatients [53] and
mean doses of 18–19 mg among inpatients [54]). As such, the
relevance of these data to patients with schizophrenia or bipolar
disorder requires further study, and future research on the
metabolic effects and mechanism of action of OLZ/SAM in patient
populations should take these considerations into account. Finally,
the adjustments to the regression model may not have fully
corrected for the postrandomization imbalance in race between
the treatment groups. This study was strengthened by the fact
that it was metabolically controlled. The inclusion of healthy
subjects who were free of underlying metabolic issues that might
confound assessments also fortiﬁes these ﬁndings [2, 24, 25].
Overall, OLZ/SAM was generally well tolerated, with an AE proﬁle
similar to that observed in a previous study of OLZ/SAM in healthy
volunteers [55]. In this study, olanzapine and OLZ/SAM elicited
early metabolic changes that preceded substantial or prolonged
weight gain. Moreover, although the two treatments resulted in
similar effects on lipid metabolism, they exhibited different effects
on glucose metabolism and insulin sensitivity. For example,
treatment with OLZ/SAM appeared to mitigate olanzapineinduced hyperinsulinemia and decline in the Matsuda index with
OGTT and normalized the initial rise in the HIR index, ﬁndings that
mirror early metabolic changes observed in recent nonclinical
studies conducted in rodents and nonhuman primates [22]. These
differences occurred when the weight gain proﬁles were similar
and suggest differences in drug effects that are independent of
weight. Although samidorphan has a pharmacodynamic proﬁle
distinct from that of olanzapine, they both may modulate relevant
physiologic processes, including glucose and lipid metabolism.

REFERENCES
1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N
Engl J Med. 2005;353:1209–23.
2. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol.
2012;8:114–26.
3. Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al.
Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry.
2017;174:686–94.
4. Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM. Atypical
antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Psychopharmacol Bull. 2009;42:11–31.
5. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential
effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on
type 2 diabetes: ﬁndings from a large health plan database. J Clin Psychiatry.
2002;63:920–30.

6. Koro CE, Fedder DO, L’Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An
assessment of the independent effects of olanzapine and risperidone exposure
on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry.
2002;59:1021–6.
7. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al.
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J
Psychiatry. 1999;156:1686–96.
8. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative
efﬁcacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013;382:951–62.
9. Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices:
an analysis of data from a large midwestern state. J Clin Psychiatry.
2012;73:498–503.
10. Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy:
results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin.
2006;22:2345–53.
11. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine
in healthy volunteers. PLoS ONE. 2011;6:e22662.
12. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled,
double-blind multicenter comparison of the efﬁcacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–47.
13. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al.
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective
disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37:352–61.
14. Daurignac E, Leonard KE, Dubovsky SL. Increased lean body mass as an early
indicator of olanzapine-induced weight gain in healthy men. Int Clin Psychopharmacol. 2015;30:23–8.
15. Alkermes, Inc. Lybalvi [package insert]. Waltham, MA: Alkermes, Inc.; 2021.
16. Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, et al. Syntheses of novel high
afﬁnity ligands for opioid receptors. Bioorg Med Chem Lett. 2009;19:2289–94.
17. Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, et al. In
vitro pharmacological characterization of buprenorphine, samidorphan, and
combinations being developed as an adjunctive treatment of major depressive
disorder. J Pharm Exp Ther. 2018;367:267–81.
18. Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Use of remifentanil in a
novel clinical paradigm to characterize onset and duration of opioid blockade by
samidorphan, a potent mu-receptor antagonist. J Clin Psychopharmacol.
2015;35:242–9.
19. Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation
of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a
randomized double-blind phase 2 study in patients with schizophrenia. Am J
Psychiatry. 2019;176:457–67.
20. Potkin SG, Silverman BL, Simmons A, Jiang Y, DiPetrillo L, McDonnell D. A phase
3 study to determine the antipsychotic efﬁcacy and safety of ALKS 3831 in adult
patients with acute exacerbation of schizophrenia [poster T214]. Presented at:
Annual Congress of the American College of Neuropsychopharmacology, Palm
Springs, CA, 3–7 December, 2017.
21. Correll CU, Kahn R, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al. A combination of olanzapine and samidorphan mitigates the weight gain observed with
olanzapine alone: results from the phase 3 ENLIGHTEN-2 schizophrenia study
[poster]. Presented at: Annual Congress of the Schizophrenia International
Research Society, Orlando, FL, 10–14 April 2019.
22. Cunningham JI, Eyerman DJ, Todtenkopf MS, Dean RL, Deaver DR, Sanchez C,
et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic
dysfunction in rats and nonhuman primates. J Psychopharmacol.
2019;33:1303–16.
23. Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al.
Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177:1168–78.
24. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De, et al. Prevalence of
metabolic syndrome and metabolic abnormalities in schizophrenia and related
disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39:306–18.
25. Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in
schizophrenia: a review. Ther Adv Psychopharmacol. 2013;3:33–51.
26. Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia-suicide
severity rating scale (C-SSRS) since last visit. Columbia University Medical Center,
2009. Available at: https://cssrs.columbia.edu/wp-content/uploads/C-SSRS1-1409-SinceLastVisit.pdf. Accessed: 31 March 2021.
27. American Psychiatric Publishing. Diagnostic and Statistical Manual of Mental
Disorders, DSM-5. 5th edn. Washington, DC: American Psychiatric Publishing;
2013.

Neuropsychopharmacology (2022) 47:696 – 703

F.G.S. Toledo et al.

703
28. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin
resistance indexes derived from the oral glucose tolerance test. Diabetes Care.
2007;30:89–94.
29. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R,
et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy
volunteers. Neuropsychopharmacology 2008;33:1633–41.
30. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychoticinduced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013;62:3232–40.
31. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, Roelfsema F, Romijn JA, Pijl H.
Effects of olanzapine and haloperidol on the metabolic status of healthy men. J
Clin Endocrinol Metab. 2010;95:118–25.
32. Filakovic P, Koic O, Laufer D, Radanovic-Grguric L, Degmecic D, Pozgain I. Second
generation antipsychotics and risk of diabetes type II-comparison between
olanzapine and risperidone. Coll Antropol. 2007;31:1105–9.
33. Sato Y, Yasui-Furukori N, Furukori H, Saito M, Nakagami T, Kaneko S. A crossover
study on the glucose metabolism between treatment with olanzapine and
risperidone in schizophrenic patients. Exp Clin Psychopharmacol.
2010;18:445–50.
34. Rickels MR, Perez EM, Peleckis AJ, Alshehabi E, Nguyen HL, Stefanovski D, et al.
Contribution of parasympathetic muscarinic augmentation of insulin secretion to
olanzapine-induced hyperinsulinemia. Am J Physiol Endocrinol Metab. 2018;315:
E250–e7.
35. Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, et al. Atypical antipsychotics
and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor
binding on insulin secretion in vivo: an animal model. Schizophr Res.
2011;131:90–5.
36. Farino ZJ, Morgenstern TJ, Maffei A, Quick M, De Solis AJ, Wiriyasermkul P, et al.
New roles for dopamine D(2) and D(3) receptors in pancreatic beta cell insulin
secretion. Mol Psychiatry. 2020;25:2070–85.
37. Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, et al.
Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic
and dopaminergic receptors. Transl Psychiatry. 2021;11:59.
38. Ipp E, Schusdziarra V, Harris V, Unger RH. Morphine-induced hyperglycemia: role
of insulin and glucagon. Endocrinology 1980;107:461–3.
39. Green IC, Perrin D, Pedley KC, Leslie RD, Pyke DA. Effect of enkephalins and
morphine on insulin secretion from isolated rat islets. Diabetologia
1980;19:158–61.
40. Green IC, Ray K, Perrin D. Opioid peptide effects on insulin release and c-AMP in
islets of Langerhans. Horm Metab Res. 1983;15:124–8.
41. Ahrén B, Lundquist I. Effects of naloxone on basal and stimulated insulin secretion in the mouse. Eur J Pharm. 1984;102:135–9.
42. Radosevich PM, Williams PE, Lacy DB, McRae JR, Steiner KE, Cherrington AD, et al.
Effects of morphine on glucose homeostasis in the conscious dog. J Clin Invest.
1984;74:1473–80.
43. van Loon GH, Appel NM. beta-Endorphin-induced hyperglycemia is mediated by
increased central sympathetic outﬂow to adrenal medulla. Brain Res.
1981;204:236–41.
44. Fulghesu AM, Lanzone A, Cucinelli F, Caruso A, Mancuso S. Long-term naltrexone
treatment reduces the exaggerated insulin secretion in patients with polycystic
ovary disease. Obstet Gynecol. 1993;82:191–7.
45. Singh A, Gibert Y, Dwyer KM. The adenosine, adrenergic and opioid pathways in
the regulation of insulin secretion, beta cell proliferation and regeneration.
Pancreatology 2018;18:615–23.
46. Verspohl EJ, Berger U, Ammon HP. The signiﬁcance of mu- and delta-receptors in
rat pancreatic islets for the opioid-mediated insulin release. Biochim Biophys
Acta. 1986;888:217–24.
47. Muniyappa R, Madan R. Assessing insulin sensitivity and resistance in humans. In:
Feingold KR, Anawalt B, Boyce A, editors. Endotext [Internet]. South Dartmouth,
MA: MDText.com, Inc.; 2018.
48. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26:19–39.
49. Tonelli J, Kishore P, Lee DE, Hawkins M. The regulation of glucose effectiveness:
how glucose modulates its own production. Curr Opin Clin Nutr Metab Care.
2005;8:450–6.
50. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al.
Increased food intake and energy expenditure following administration of
olanzapine to healthy men. Obesity (Silver Spring). 2010;18:1646–51.
51. Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus
patients. J Clin Psychiatry. 2001; 62 Suppl 5: 10–3; discussion 23–4.
52. Eli Lilly and Company. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and
Company; 2018.
53. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Realworld effectiveness of antipsychotic treatments in a nationwide cohort of 29823
patients with schizophrenia. JAMA Psychiatry. 2017;74:686–93.

Neuropsychopharmacology (2022) 47:696 – 703

54. Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, Greil W, et al. Psychopharmacological treatment of schizophrenia over time in 30 908 inpatients: data
from the AMSP study. Int J Neuropsychopharmacol. 2019;22:560–73.
55. Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate
samidorphan in the prevention of olanzapine-induced weight gain in healthy
volunteers. Schizophr Res. 2018;195:245–51.

ACKNOWLEDGEMENTS
This study was sponsored by Alkermes, Inc. The authors thank Mark S. Todtenkopf,
PhD, who assisted in the preparation and proofreading of the manuscript, and the
ALK3831-A108 study group. Medical writing and editorial support were provided by
Gina Daniel, PhD, and John H. Simmons, MD, of Peloton Advantage, LLC, an OPEN
Health company, and funded by Alkermes, Inc.

AUTHOR CONTRIBUTIONS
All authors had full access to the data and contributed to the drafting, critical review,
and revision of the manuscript, with the support of medical writers provided by
Alkermes, Inc. All authors granted approval of the ﬁnal manuscript for submission.

FUNDING INFORMATION
Alkermes, Inc., is a pharmaceutical company that developed OLZ/SAM, a combination
of olanzapine and samidorphan approved for the treatment of adults with
schizophrenia or bipolar I disorder, and has funded this study. Medical writing and
editorial support was provided by Peloton Advantage, LLC, an OPEN Health company,
and funded by Alkermes, Inc.

COMPETING INTERESTS
FGST has received consulting honoraria from Alkermes, Inc. BLS, WFM, YJ, and MNN
were employees of Alkermes, Inc., at the time of this study. CG is an employee of
Alkermes, Inc. LM and CB are employees and shareholders in ProSciento, Inc. DB was
an employee of Vault Bioventures at the time of this study and has served as a
consultant for Alkermes, Inc. DM is an employee of Alkermes Pharma Ireland Ltd. JWN
has received grant support from the National Institutes of Health and the Substance
Abuse and Mental Health Services Administration, has served as a consultant for
Alkermes, Inc., Intra-cellular Therapies, Inc., and Sunovion, and served on a Data
Safety Monitoring Board for Amgen.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41386-021-01244-7.
Correspondence and requests for materials should be addressed to Christine
Graham.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2021

